M Ventures is the strategic, corporate venture capital fund of Merck KGaA, Darmstadt, Germany, investing in Biotechnology and Technology. We cover the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability.

Biotechnology. Targeting some of the most challenging diseases, disruptive tools and technologies for R&D and manufacturing. With our Biotech portfolio, we focus on investing in emerging biotechnologies leading to differentiated products, R&D tools, platforms, modalities with the potential to significantly improve patient outcomes and drug development processes.

Meet the people behind our investments that have been instrumental in the creation, financing and management of our portfolio companies.

M Ventures Invests in TIGNIS for Sustainability in Semiconductor Mfg. in Series A; 2022/06/09 Metalenz and STMicroelectronics Deliver World’s First Optical Metasurface Technology for Consumer Electronics Devices; 2022/06/08 Scipio bioscience selected for €2.5M European Innovation Council grant; 2022/05/31

Jan 21, 2025 · NovoLINC, a thermal technology startup spun out of Carnegie Mellon University, announced seed funding led by M Ventures, with participation from Foothill Ventures and TDK Ventures.

Jan 8, 2024 · Calypso was founded by M Ventures, the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany, and is headquartered in Amsterdam, The Netherlands, with offices and laboratories in Geneva, Switzerland.

Jun 28, 2016 · The investment syndicate of Imperial Innovations, Cambridge Innovation Capital, M Ventures and Pfizer Venture Investments is delighted to be working with the founders and management team to make Storm Therapeutics a leader in therapeutic modulation of RNA modifying enzymes.”

The entire content of this Site is the property of M Ventures, its direct or indirect subsidiaries or third parties and is protected by applicable copyright law with all rights reserved. All rights in the pages, site content and arrangement are owned by M Ventures and its licensors.

May 21, 2024 · The round was led by new investor M Ventures (the strategic, corporate venture capital arm of science and technology company Merck KGaA, Darmstadt, Germany), with participation from additional new investors Octopus Ventures and LG Corp, together with existing investors including Atomico, Kindred Capital, Lux Capital and Obvious Ventures.

Dec 8, 2021 · M Ventures’ focus on identifying and financing novel solutions to some of the most difficult challenges, can be evidenced through its early investments into companies such as Artios Pharma, DNA Script, Memryx, Mosa Meat, Padlock Therapeutics, Progyny Inc, and SeeQC, in addition to many others.